researchmapはコチラから

Original Articles:

34. 

Shidahara K, Katsuyama T, Hirose K, Matsumoto K, Nawachi S, Nakadoi T, Asano Y, Katayama Y, Miyawaki Y, Katsuyama E, Narazaki M, Matsumoto Y, Sada KE, Wada J. Infliximab biosimilar-induced lupus nephritis: a case report. Mod. Rheumatol. Case Rep. 2023. 8(1): 74-76.

33. 

Matsumoto K, Miyawaki Y, Katsuyama T, Nakadoi T, Shidahara K, Hirose K, Nawachi S, Asano Y, Katayama Y, Katsuyama E, Narazaki M, Matsumoto Y, Mori A, Akagi S, Sada KE, Wada J. Immunosuppressive treatment for an anti-U1 ribonucleoprotein antibody-positive patient with pulmonary arterial hypertension: a case report. 2023. 

32.

Miyawaki Y, Sada KE, Shidahara K, Nawachi S, Asano Y, Katayama Y, Hayashi K, Katsuyama E, Katsuyama T, Narazaki M, Matsumoto Y, Oguro N, Yajima N, Ishikawa Y, Sakurai N, Hidekawa C, Yoshimi R, Ichikawa T, Kishida D, Shimojima Y, Wada J, Kurita N. The association of grit with burnout components (Professional Efficacy, Exhaustion, and Cynicism) among academic rheumatologists: The TRUMP 2-SLE study. J. Clin. Rheumatol. 2023. 29 (6): 268-274.

31. 

Watanabe H, Kubo M, Taniguchi A, Asano Y, Asano S, Ohashi K, Zeggar S, Katsuyama E, Katsuyama T, Watanabe K, Sada KE, Matsumoto Y, Yamamoto Y, Yamamoto H, Son M, Wada J. Amelioration of nephritis in receptor for advanced glycation end-products (RAGE)-deficient lupus-prone mice through neutrophil extracellular traps. Clin. Immunol. 2023, 250: 109317. 

30. 

Katayama Y, Miyawaki Y, Shidahara K, Nawachi S, Asano Y, Ohashi K, Katsuyama E, Katsuyama T, Narazaki M, Matsumoto Y, Sada KE, Yajima N, Shimojima Y, Yoshimi R, Ichinose K, Kajiyama H, Fujiwara M, Sato S, Wada J. Association of alcohol consumption and fatigue in SLE: A cross-sectional study from Lupus Registry of Nationwide Institution (LUNA) cohort. 2023, 32 (4): 531-537. 

29. 

Sasaki R, Yunoki T, Nakano Y, Fukui Y, Takemoto M, Morihara R, Kastuyama E, Nishino I, YamashitaT. A young female case of asymptomatic immune-mediated necrotizing myopathy: a potential diagnostic option of antibody testing for rhabdomyolysis. Neuromuscul. Disord. 2023. 3(2): 183-186. 

28. 

Asano Y, Matsumoto Y, He F, Katsuyama T, Katsuyama E, Tsuji S, Kamioka H, Rose JL, Rottapel R, Wada J. Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through differenct pathways. Clin. Exp. Rheumatol. 2023 41(9): 1735-1745.

27. 

Nakadoi T, Katsuyama E, Matsumoto K, Shidahara K, Hirose K, Nawachi S, Asano Y, Katayama Y, Miyawaki Y, Katsuyama T, Narazaki M, Matsumoto Y, Sada KE, Tada H, Wada J. A case of sitosterolaemia-caused systemic large-vessel stenosis mimicking Takayasu arteritis in which FDG-PET provided a clue for the differential diagnosis. Rheumatology Advances in Practice. 2023. 7(3): rkad096. 

26.

Sada KE, Miyawaki Y, Shidahara K, Nawachi S, Katayama Y, Asano Y, Hayashi K, Ohashi K, Katsuyama E, Katsuyama T, Takano-Narazaki M, Matsumoto Y, Oguro N, Ishikawa Y, Sakurai N, Hidekawa C, Yoshimi R, Kishida D, Ichikawa T, Shimojima Y, Kurita N, Yajima N. Grit personality of physicians and achievement of treatment goals in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022 Oct 20:keac612. 《PubMed》

25. 

Sada KE, Katayama Y, Asano Y, Hayashi K, Miyawaki Y, Ohashi K, Katsuyama E, Katsuyama T, Takano-Narazaki M, Matsumoto Y, Yoshimi R, Shimojima Y, Ohno S, Kajiyama H, Ichinose K, Sato S, Fujiwara M, Yajima N. Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study. Lupus Sci Med. 2022 Sep;9(1):e000772. 《PubMed》

24.

Inagaki J, Nakano A, Hatipoglu OF, Ooka Y, Tani Y, Miki A, Ikemura K, Opoku G, Ando R, Kodama S, Ohtsuki T, Yamaji H, Yamamoto S, Katsuyama E, Watanabe S, Hirohata S. Potential of a Novel Chemical Compound Targeting Matrix Metalloprotease-13 for Early Osteoarthritis: An In Vitro Study. Int J Mol Sci. 2022 Feb 28;23(5):2681. 《PubMed》

23.

Chen PM, Katsuyama E, Satyam A, Li H, Rubio J, Jung S, Andrzejewski S, Becherer JD, Tsokos MG, Abdi R, Tsokos GC. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci Adv. 2022 Jun 17;8(24):eabo4271. 《PubMed》

22.

Alves de Souza RW, Gallo D, Lee GR, Katsuyama E, Schaufler A, Weber J, Csizmadia E, Tsokos GC, Koch LG, Britton SL, Wisløff U, Brum PC, Otterbein LE. Skeletal muscle heme oxygenase-1 activity regulates aerobic capacity. Cell Rep. 2021 Apr 20;35(3):109018. 《PubMed》

21. 

Hiramatsu-Asano S, Sunahori-Watanabe K, Zeggar S, Katsuyama E, Mukai T, Morita Y, Wada J. Deletion of Mir223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Fas lpr/lpr Mice. Front Immunol. 2021 Jan 26;11:616141. 《PubMed》

20.

Ohashi K, Sada KE, Asano Y, Hayashi K, Yamamura Y, Asano SH, Miyawaki Y, Morishita M, Katsuyama E, Watanabe H, Tatebe N, Narazaki M, Matsumoto Y, Sunahori-Watanabe K, Kawabata T, Yajima N, Wada J. Risk Factors for Chronic Damage Accumulation Across Different Onset Eras in Systemic Lupus Erythematosus: A Cross-sectional Analysis of a Lupus Registry of Nationwide Institutions (LUNA).  Acta Med Okayama. 2020 Jun;74(3):191-198. 《PubMed》

19.

Katsuyama E, Miyawaki Y, Sada KE, Asano Y, Hayashi K, Yamamura Y, Hiramatsu-Asano S, Morishita M, Ohashi K, Watanabe H, Katsuyama T, Narazaki M, Matsumoto Y, Wada J. Association of explanatory histological findings and urinary protein and serum creatinine levels at renal biopsy in lupus nephritis: a cross-sectional study.  BMC Nephrol. 2020 Jun 1;21(1):208. 《PubMed》

18. 

Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, Krishfield S, Malavasi F, Yoon J, Sui SJH, Kyttaris VC, Tsokos GC. The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections. Cell Rep. 2020 Jan 7;30(1):112-123.e4. 《PubMed》

17. Suarez-Fueyo A, Tsokos MG, Kwok SK, Maeda K, Katsuyama E, Lapchak PH, Tsokos GC. Hyaluronic Acid Synthesis Contributes to Tissue Damage in Systemic Lupus Erythematosus. Front Immunol. 2019 Sep 13;10:2172. 《PubMed》

16. Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger JA, Herzog RW, Engel P, Terhorst C. SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 Sep;7(9):1485-1496. 《PubMed》

15.

Morishita M, Sada KE, Matsumoto Y, Hayashi K, Asano Y, Hiramatsu Asano S, Ohashi K, Miyawaki Y, Katsuyama E, Watanabe H, Kawabata T, Wada J. Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2019 Jul 10;14(7):e0218705. 《PubMed》

14.

Kono M, Maeda K, Stocton-Gavanescu I, Pan W, Umeda M, Katsuyama E, Burbano C, Orite SYK, Vukelic M, Tsokos MG, Yoshida N, Tsokos GC. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight. 2019 Jun 20;4(12):e127395 《PubMed》

13.

Hiramatsu S, Watanabe KS, Zeggar S, Asano Y, Miyawaki Y, Yamamura Y, Katsuyama E, Katsuyama T, Watanabe H, Takano-Narazaki M, Matsumoto Y, Kawabata T, Sada KE, Wada J. Regulation of Cathepsin E gene expression by the transcription factor Kaiso in MRL/lpr mice derived CD4+ T cells. Sci Rep. 2019 Feb 28;9(1):3054. 《PubMed》

12.

Karampetsou MP, Comte D, Suárez-Fueyo A, Katsuyama E, Yoshida N, Kono M, Kyttaris VC, Tsokos GC. Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cell-B Cell Interaction and Diminishes Interleukin-6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Jan;71(1):99-108. 《PubMed》

11.

Ohashi K, Sada KE, Nakai Y, Matsushima S, Asano Y, Hayashi K, Yamamura Y, Hiramatsu S, Miyawaki Y, Morishita M, Katsuyama T, Katsuyama E, Watanabe H, Tatebe N, Narazaki M, Matsumoto Y, Sunahori Watanabe K, Kawabata T, Wada J. Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis. J Clin Rheumatol. 2019 Sep;25(6):246-251. 《PubMed》

10.

Suárez-Fueyo A, Bradley SJ, Katsuyama T, Solomon S, Katsuyama E, Kyttaris VC, Moulton VR, Tsokos GC. Downregulation of CD3ζ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype. J Immunol. 2018 May 1;200(9):3077-3086.   《PubMed》

9.

Zeggar S, Watanabe KS, Teshigawara S, Hiramatsu S, Katsuyama T, Katsuyama E, Watanabe H, Matsumoto Y, Kawabata T, Sada KE, Niki T, Hirashima M, Wada J. Role of Lgals9 deficiency attenuates nephritis and arthritis in pristane-induced lupus model of BALB/c mice. Arthritis Rheumatol. 2018 Jul;70(7):1089-1101. 《PubMed》

8.

Morishita M, Watanabe H, Yan M, Zeggar S, Hiramatsu S, Ohashi K, Miyawaki Y, Katsuyama E, Katsuyama T, Takano Narazaki M, Toyota Tatebe N, Sunahori Watanabe K, Kawabata T, Sada KE, Wada J. Azathioprine Intolerance in Japanese Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Intern Med. 2017;56(13):1645-1650. 《PubMed》

7.

Watanabe H, Sunahori-Watanabe K, Liu K, Hiramatsu S, Zeggar S, Katsuyama E, Tatebe N, Akahoshi A, Takenaka F, Hanada T, Akehi M, Sasaki T, Sada KE, Matsuura E, Nishibori M, Wada J. Anti-high  Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lprLupus-Prone Mice. Mol Ther Methods Clin Dev. 2017 May 25;6:31-39. 《PubMed》

6.

Miyawaki Y, Katsuyama T, Sada KE, Hiramatsu S, Ohashi K, Morishita M, Katsuyama E, Watanabe H, Takano-Narazaki M, Toyota-Tatebe N, Sunahori-Watanabe K, Kawabata T, Inoue T, Kinomura M, Sugiyama H, Wada J. A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. PLoS One. 2017 May 31;12(5):e0178018 《PubMed》

5. 

Tatebe N, Sada KE, Asano Y, Zeggar S, Hiramatsu S, Miyawaki Y, Ohashi K, Morishita M, Katsuyama T, Katsuyama E, Watanabe H, Narazaki M, Watanabe K, Kawabata T, Wada J. Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. Mod Rheumatol. 2018 Jan;28(1):141-146. 《PubMed》

4. 

Katsuyama E, Yan M, Watanabe SK, Matsushima S, Yamamura Y, Hiramatsu S, Ohashi K, Watanabe H, Katsuyama T, Zeggar S, Yoshida N, Moulton VR, Tsokos GC, Sada KE, Wada J. Down-regulation of miR-200a-3p, targeting C-terminal binding protein-2 (CtBP2) complex, is involved in the hypoproduction of IL-2 in SLE-derived T cells. J Immunol. 2017 Jun 1;198(11):4268-4276. 《PubMed》

3.

Katsuyama T, Sada KE, Yan M, Zeggar S, Hiramatsu S, Miyawaki Y, Ohashi K, Morishita M, Watanabe H, Katsuyama E, Takano-Narazaki M, Toyota-Tatebe N, Sunahori-Watanabe K, Kawabata T, Miyake K, Kiguchi T, Wada J. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol. 2017 Sep;27(5):773-777. 《PubMed》

2.  

Watanabe H, Yamanaka R, Sada KE, Zeggar S, Katsuyama E, Katsuyama T, Takano-Narazaki M, Tatebe-Toyota N, Sugiyama K, Wakabayashi H, Kawabata T, Wada J, Makino H. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus. 2016 Jan;25(1):54-60. 《PubMed》

1.

Katsuyama T, Sada KE, Namba S, Watanabe H, Katsuyama E, Yamanari T, Wada J, Makino H. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015 May;108(2):273-9. 《PubMed》

Case Reports: 

5.

Katayama Y, Katsuyama T, Shidahara K, Nawachi S, Asano Y, Ohashi K, Miyawaki Y, Katsuyama E, Narazaki M, Matsumoto Y, Sada KE, Wada J. A case of recurrent IgG4-related disease successfully treated with belimumab after remission of systemic lupus erythematosus. Rheumatology (Oxford). 2022 Oct 6;61(10):e308-e310. 《PubMed》

4.

Ohashi K, Morishita M, Watanabe H, Sada KE, Katsuyama T, Miyawaki Y, Katsuyama E, Narazaki  M, Tatebe N, Watanabe K, Kawabata T, Wada J. Central Diabetes Insipidus in Refractory Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Intern Med. 2017 Nov1;56(21):2943-2948. 《PubMed》

3.

Katsuyama E, Wakabayashi H, Sada KE, Hiramatsu S, Miyawaki Y, Morishita M, Ohashi K, Watanabe H, Katsuyama T, Zeggar S, Narazaki M, Tatebe N, Sunahori-Watanabe K, Kawabata T, Wada J. Alternative to Rituximab Therapy for a Patient with Ankylosing Spondylitis Who Was Unable to Continue Anti-TNF Therapy. Acta Med Okayama. 2017 Oct;71(5):445-448. 《PubMed》

2.

Katsuyama E, Sada KE, Tatebe N, Watanabe H, Katsuyama T, Narazaki M, Sugiyama K, Watanabe SK, Wakabayashi H, Kawabata T, Wada J, Makino H. Bilateral Abducens Nerve Palsy Due to Idiopathic Intracranial Hypertension as an Initial Manifestation of Systemic Lupus Erythematosus. Intern Med. 2016;55(8):991-4. 《PubMed》

1.

Hirakawa E (旧姓), Saito K, Hirata S, Atsumi T, Koike T, Tanaka Y. A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β₂ glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. Mod Rheumatol. 2012 Sep;22 (5):769-73. 《PubMed》